Matsuda Isao, Mori Yuki, Nakagawa Yasunori, Sawanobori Masakazu, Uemura Naoki, Suzuki Kenshi
Department of Hematology, Japanese Red Cross Medical Center.
Rinsho Ketsueki. 2005 Dec;46(12):1293-7.
Stratification of patients with multiple myeloma (MM) may be important. We investigated 138 MM patients, focusing on correlations between CD20 expression, 11 ; 14 translocation, morphology of MM cells, cyclin D1 immunostaining, and the prognosis. About 15% of patients (7/47cases) were CD20-positive, small mature MM cells, with positive cyclin D1 in the nucleus and 11; 14 translocation. Two color analysis of CD38 x CD20 antigens may be necessary to investigate CD20 expression on MM cells. Rituximab may be effective for the treatment of CD20-positive MM.
对多发性骨髓瘤（MM）患者进行分层可能很重要。我们研究了138例MM患者，重点关注CD20表达、11；14易位、MM细胞形态、细胞周期蛋白D1免疫染色与预后之间的相关性。约15%的患者（7/47例）为CD20阳性，小的成熟MM细胞，细胞核中细胞周期蛋白D1呈阳性且有11；14易位。可能需要对CD38×CD20抗原进行双色分析以研究MM细胞上的CD20表达。利妥昔单抗可能对CD20阳性MM的治疗有效。
